Overview: Pfizer stock is trading near $25.86 with moderate upside potential based on the forecast range of up to ...

In the last six months Pfizer’s stock (NYSE: PFE) has underperformed Merck (NYSE: MRK) and J&J (NYSE: JNJ) primarily due to ...

Pfizer has lagged the broader market over the past year, and analysts remain cautious about its future outlook.

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Pfizer may look cheap with a ~7% yield, but tight free cash flow, patent cliffs, and limited growth raise downside risk. Read ...

The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.

Pfizer Inc. (PFE) shares are trading higher on Tuesday, as the stock benefits from a price target increase at Cantor ...

Pfizer is one of the world's largest pharmaceutical companies. Even after losing more than half of its value, it still has a ...

Pfizer PFE stock has declined almost 5% in a month, losing $7.3 billion in market capitalization. Shares dipped recently after the company announced its financial guidance for 2026, which fell short ...

Pfizer Inc. has a 6% yield and 8.49x P/E with new cancer drugs and GLP-1 therapies to offset 2026-2028 LOE cycles. Read why ...

Pfizer PFE is set to report its fourth-quarter and full-year 2025 earnings on Feb. 3, before market open. The Zacks Consensus Estimate for sales and earnings for the fourth quarter is pegged at $16.93 ...

Promising clinical results in 2026 could set the stage for Pfizer's stock to rebound. However, the company's COVID-19 product and patent cliff challenges could prevent a big bounce this year. Even if ...